Clinical Trial Update: Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome [Phase 3]

View source ↗

Summary

Open-label extension study of DCCR for Prader-Willi Syndrome in Phase 3 is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• DCCR (diazoxide choline)

Snippet

Sponsor: Soleno Therapeutics, Inc. | Conditions: Prader-Willi Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING